APO Research
Talk to an analyst

APO RESEARCH · REPORT

Interleukin 1 (IL1)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Interleukin 1 (IL1) Market Outlook and Growth Opportunities 2026

19 December 2025202 pages

Choose your research edition.

Industry ResearchInterleukin 1 (IL1) Industry Research Report 2026136 pages · $2,950 USDIndustry Growth & TrendsGlobal Interleukin 1 (IL1) Industry Growth and Trends Forecast to 2032118 pages · $3,450 USDMarket StructureGlobal Interleukin 1 (IL1) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Interleukin 1 (IL1) Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Interleukin 1 (IL1) Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Interleukin 1 (IL1) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Interleukin 1 (IL1) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Interleukin 1 (IL1) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Interleukin 1 (IL1) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Interleukin 1 (IL1) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Interleukin 1 (IL1) market include Novartis AG, AbbVie Inc, XBiotech Inc, TWi Biotechnology Inc, Swedish Orphan Biovitrum AB, Regeneron Pharmaceuticals Inc, R Pharm, Peptinov SAS and Orphit SAS, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Interleukin 1 (IL1) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Interleukin 1 (IL1) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Interleukin 1 (IL1) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Interleukin 1 (IL1) market size, projected growth trends, production technologies, key applications, and end-use industries.

Interleukin 1 (IL1) Segment by Company

Novartis AG

AbbVie Inc

XBiotech Inc

TWi Biotechnology Inc

Swedish Orphan Biovitrum AB

Regeneron Pharmaceuticals Inc

R Pharm

Peptinov SAS

Orphit SAS

Optimum Therapeutics LLC

Opsona Therapeutics Ltd

Omnitura Therapeutics Inc

Immune Response BioPharma Inc

Exicure Inc

Cell Medica Ltd

Apexigen Inc

Anacor Pharmaceuticals Inc

Interleukin 1 (IL1) Segment by Type

APX-002

Diacerein CR

Canakinumab

IR-1000

Others

Interleukin 1 (IL1) Segment by Application

Fallopian Tube Cancer

Esophageal Cancer

Bechcer Disease

Bladder Cancer

Others

Interleukin 1 (IL1) Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Interleukin 1 (IL1) status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Interleukin 1 (IL1) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Interleukin 1 (IL1) significant trends, drivers, influence factors in global and regions.

6. To analyze Interleukin 1 (IL1) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Interleukin 1 (IL1) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Interleukin 1 (IL1) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Interleukin 1 (IL1).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Interleukin 1 (IL1) market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Interleukin 1 (IL1) industry.

Chapter 3: Detailed analysis of Interleukin 1 (IL1) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Interleukin 1 (IL1) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Interleukin 1 (IL1) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Interleukin 1 (IL1) Industry Trends Table 2. Interleukin 1 (IL1) Industry Drivers Table 3. Interleukin 1 (IL1) Industry Opportunities and Challenges Table 4. Interleukin 1 (IL1) Industry Restraints Table 5. Global Interleukin 1 (IL1) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Interleukin 1 (IL1) Revenue Share by Company (2021-2026) Table 7. Global Interleukin 1 (IL1) Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Interleukin 1 (IL1) Sales Volume Share by Company (2021-2026) Table 9. Global Interleukin 1 (IL1) Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Interleukin 1 (IL1) Company Ranking, (2024-2026) & (USD Million) Table 11. Global Interleukin 1 (IL1) Key Company Manufacturing Base & Headquarters Table 12. Global Interleukin 1 (IL1) Company, Product Type & Application Table 13. Global Interleukin 1 (IL1) Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Interleukin 1 (IL1) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of APX-002 Table 18. Significant Companies of Diacerein CR Table 19. Significant Companies of Canakinumab Table 20. Significant Companies of IR-1000 Table 21. Significant Companies of Others Table 22. Global Interleukin 1 (IL1) Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global Interleukin 1 (IL1) Sales Volume by Type (2021-2026) & (K Units) Table 24. Global Interleukin 1 (IL1) Sales Volume by Type (2027-2032) & (K Units) Table 25. Global Interleukin 1 (IL1) Sales Volume Share by Type (2021-2026) Table 26. Global Interleukin 1 (IL1) Sales Volume Share by Type (2027-2032) Table 27. Global Interleukin 1 (IL1) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Interleukin 1 (IL1) Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Interleukin 1 (IL1) Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Interleukin 1 (IL1) Sales Value Share by Type (2021-2026) Table 31. Global Interleukin 1 (IL1) Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Fallopian Tube Cancer Table 33. Significant Companies of Esophageal Cancer Table 34. Significant Companies of Bechcer Disease Table 35. Significant Companies of Bladder Cancer Table 36. Significant Companies of Others Table 37. Global Interleukin 1 (IL1) Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Interleukin 1 (IL1) Sales Volume by Application (2021-2026) & (K Units) Table 39. Global Interleukin 1 (IL1) Sales Volume by Application (2027-2032) & (K Units) Table 40. Global Interleukin 1 (IL1) Sales Volume Share by Application (2021-2026) Table 41. Global Interleukin 1 (IL1) Sales Volume Share by Application (2027-2032) Table 42. Global Interleukin 1 (IL1) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Interleukin 1 (IL1) Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Interleukin 1 (IL1) Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Interleukin 1 (IL1) Sales Value Share by Application (2021-2026) Table 46. Global Interleukin 1 (IL1) Sales Value Share by Application (2027-2032) Table 47. Global Interleukin 1 (IL1) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Interleukin 1 (IL1) Sales by Region (2021-2026) & (K Units) Table 49. Global Interleukin 1 (IL1) Sales Market Share by Region (2021-2026) Table 50. Global Interleukin 1 (IL1) Sales by Region (2027-2032) & (K Units) Table 51. Global Interleukin 1 (IL1) Sales Market Share by Region (2027-2032) Table 52. Global Interleukin 1 (IL1) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Interleukin 1 (IL1) Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Interleukin 1 (IL1) Sales Value Share by Region (2021-2026) Table 55. Global Interleukin 1 (IL1) Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Interleukin 1 (IL1) Sales Value Share by Region (2027-2032) Table 57. Global Interleukin 1 (IL1) Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Interleukin 1 (IL1) Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Interleukin 1 (IL1) Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global Interleukin 1 (IL1) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Interleukin 1 (IL1) Sales by Country (2021-2026) & (K Units) Table 62. Global Interleukin 1 (IL1) Sales Market Share by Country (2021-2026) Table 63. Global Interleukin 1 (IL1) Sales by Country (2027-2032) & (K Units) Table 64. Global Interleukin 1 (IL1) Sales Market Share by Country (2027-2032) Table 65. Global Interleukin 1 (IL1) Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Interleukin 1 (IL1) Sales Value Market Share by Country (2021-2026) Table 67. Global Interleukin 1 (IL1) Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Interleukin 1 (IL1) Sales Value Market Share by Country (2027-2032) Table 69. Novartis AG Company Information Table 70. Novartis AG Business Overview Table 71. Novartis AG Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Novartis AG Interleukin 1 (IL1) Product Portfolio Table 73. Novartis AG Recent Development Table 74. AbbVie Inc Company Information Table 75. AbbVie Inc Business Overview Table 76. AbbVie Inc Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. AbbVie Inc Interleukin 1 (IL1) Product Portfolio Table 78. AbbVie Inc Recent Development Table 79. XBiotech Inc Company Information Table 80. XBiotech Inc Business Overview Table 81. XBiotech Inc Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. XBiotech Inc Interleukin 1 (IL1) Product Portfolio Table 83. XBiotech Inc Recent Development Table 84. TWi Biotechnology Inc Company Information Table 85. TWi Biotechnology Inc Business Overview Table 86. TWi Biotechnology Inc Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. TWi Biotechnology Inc Interleukin 1 (IL1) Product Portfolio Table 88. TWi Biotechnology Inc Recent Development Table 89. Swedish Orphan Biovitrum AB Company Information Table 90. Swedish Orphan Biovitrum AB Business Overview Table 91. Swedish Orphan Biovitrum AB Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Swedish Orphan Biovitrum AB Interleukin 1 (IL1) Product Portfolio Table 93. Swedish Orphan Biovitrum AB Recent Development Table 94. Regeneron Pharmaceuticals Inc Company Information Table 95. Regeneron Pharmaceuticals Inc Business Overview Table 96. Regeneron Pharmaceuticals Inc Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Regeneron Pharmaceuticals Inc Interleukin 1 (IL1) Product Portfolio Table 98. Regeneron Pharmaceuticals Inc Recent Development Table 99. R Pharm Company Information Table 100. R Pharm Business Overview Table 101. R Pharm Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. R Pharm Interleukin 1 (IL1) Product Portfolio Table 103. R Pharm Recent Development Table 104. Peptinov SAS Company Information Table 105. Peptinov SAS Business Overview Table 106. Peptinov SAS Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Peptinov SAS Interleukin 1 (IL1) Product Portfolio Table 108. Peptinov SAS Recent Development Table 109. Orphit SAS Company Information Table 110. Orphit SAS Business Overview Table 111. Orphit SAS Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Orphit SAS Interleukin 1 (IL1) Product Portfolio Table 113. Orphit SAS Recent Development Table 114. Optimum Therapeutics LLC Company Information Table 115. Optimum Therapeutics LLC Business Overview Table 116. Optimum Therapeutics LLC Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Optimum Therapeutics LLC Interleukin 1 (IL1) Product Portfolio Table 118. Optimum Therapeutics LLC Recent Development Table 119. Opsona Therapeutics Ltd Company Information Table 120. Opsona Therapeutics Ltd Business Overview Table 121. Opsona Therapeutics Ltd Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Opsona Therapeutics Ltd Interleukin 1 (IL1) Product Portfolio Table 123. Opsona Therapeutics Ltd Recent Development Table 124. Omnitura Therapeutics Inc Company Information Table 125. Omnitura Therapeutics Inc Business Overview Table 126. Omnitura Therapeutics Inc Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Omnitura Therapeutics Inc Interleukin 1 (IL1) Product Portfolio Table 128. Omnitura Therapeutics Inc Recent Development Table 129. Immune Response BioPharma Inc Company Information Table 130. Immune Response BioPharma Inc Business Overview Table 131. Immune Response BioPharma Inc Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Immune Response BioPharma Inc Interleukin 1 (IL1) Product Portfolio Table 133. Immune Response BioPharma Inc Recent Development Table 134. Exicure Inc Company Information Table 135. Exicure Inc Business Overview Table 136. Exicure Inc Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Exicure Inc Interleukin 1 (IL1) Product Portfolio Table 138. Exicure Inc Recent Development Table 139. Cell Medica Ltd Company Information Table 140. Cell Medica Ltd Business Overview Table 141. Cell Medica Ltd Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Cell Medica Ltd Interleukin 1 (IL1) Product Portfolio Table 143. Cell Medica Ltd Recent Development Table 144. Apexigen Inc Company Information Table 145. Apexigen Inc Business Overview Table 146. Apexigen Inc Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. Apexigen Inc Interleukin 1 (IL1) Product Portfolio Table 148. Apexigen Inc Recent Development Table 149. Anacor Pharmaceuticals Inc Company Information Table 150. Anacor Pharmaceuticals Inc Business Overview Table 151. Anacor Pharmaceuticals Inc Interleukin 1 (IL1) Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Anacor Pharmaceuticals Inc Interleukin 1 (IL1) Product Portfolio Table 153. Anacor Pharmaceuticals Inc Recent Development Table 154. Key Raw Materials Table 155. Raw Materials Key Suppliers Table 156. Interleukin 1 (IL1) Distributors List Table 157. Interleukin 1 (IL1) Customers List Table 158. Research Programs/Design for This Report Table 159. Authors List of This Report Table 160. Secondary Sources Table 161. Primary Sources List of Figures Figure 1. Interleukin 1 (IL1) Product Image Figure 2. Global Interleukin 1 (IL1) Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Interleukin 1 (IL1) Sales Value (2021-2032) & (US$ Million) Figure 4. Global Interleukin 1 (IL1) Sales (2021-2032) & (K Units) Figure 5. Global Interleukin 1 (IL1) Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Interleukin 1 (IL1) Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. APX-002 Image Figure 10. Diacerein CR Image Figure 11. Canakinumab Image Figure 12. IR-1000 Image Figure 13. Others Image Figure 14. Global Interleukin 1 (IL1) Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global Interleukin 1 (IL1) Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Interleukin 1 (IL1) Sales Volume Share by Type (2021-2032) Figure 17. Global Interleukin 1 (IL1) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Interleukin 1 (IL1) Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Interleukin 1 (IL1) Sales Value Share by Type (2021-2032) Figure 20. Fallopian Tube Cancer Image Figure 21. Esophageal Cancer Image Figure 22. Bechcer Disease Image Figure 23. Bladder Cancer Image Figure 24. Others Image Figure 25. Global Interleukin 1 (IL1) Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Interleukin 1 (IL1) Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Interleukin 1 (IL1) Sales Volume Share by Application (2021-2032) Figure 28. Global Interleukin 1 (IL1) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Interleukin 1 (IL1) Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Interleukin 1 (IL1) Sales Value Share by Application (2021-2032) Figure 31. Global Interleukin 1 (IL1) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global Interleukin 1 (IL1) Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Interleukin 1 (IL1) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Interleukin 1 (IL1) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Interleukin 1 (IL1) Sales Value (2021-2032) & (US$ Million) Figure 36. North America Interleukin 1 (IL1) Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Interleukin 1 (IL1) Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Interleukin 1 (IL1) Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Interleukin 1 (IL1) Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Interleukin 1 (IL1) Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Interleukin 1 (IL1) Sales Value (2021-2032) & (US$ Million) Figure 42. South America Interleukin 1 (IL1) Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Interleukin 1 (IL1) Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Interleukin 1 (IL1) Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Interleukin 1 (IL1) Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Interleukin 1 (IL1) Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • APX-002
  • Diacerein CR
  • Canakinumab
  • IR-1000
  • Others
Applications
  • Fallopian Tube Cancer
  • Esophageal Cancer
  • Bechcer Disease
  • Bladder Cancer
  • Others
Companies covered
  • Novartis AG
  • AbbVie Inc
  • XBiotech Inc
  • TWi Biotechnology Inc
  • Swedish Orphan Biovitrum AB
  • Regeneron Pharmaceuticals Inc
  • R Pharm
  • Peptinov SAS
  • Orphit SAS
  • Optimum Therapeutics LLC
  • Opsona Therapeutics Ltd
  • Omnitura Therapeutics Inc
  • Immune Response BioPharma Inc
  • Exicure Inc
  • Cell Medica Ltd
  • Apexigen Inc
  • Anacor Pharmaceuticals Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Interleukin 1 (IL1) Sales Value (2021-2032)
  4. 1.2.2 Global Interleukin 1 (IL1) Sales Volume (2021-2032)
  5. 1.2.3 Global Interleukin 1 (IL1) Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Interleukin 1 (IL1) Market Dynamics
  1. 2.1 Interleukin 1 (IL1) Industry Trends
  2. 2.2 Interleukin 1 (IL1) Industry Drivers
  3. 2.3 Interleukin 1 (IL1) Industry Opportunities and Challenges
  4. 2.4 Interleukin 1 (IL1) Industry Restraints
3 Interleukin 1 (IL1) Market by Company
  1. 3.1 Global Interleukin 1 (IL1) Company Revenue Ranking in 2025
  2. 3.2 Global Interleukin 1 (IL1) Revenue by Company (2021-2026)
  3. 3.3 Global Interleukin 1 (IL1) Sales Volume by Company (2021-2026)
  4. 3.4 Global Interleukin 1 (IL1) Average Price by Company (2021-2026)
  5. 3.5 Global Interleukin 1 (IL1) Company Ranking (2024-2026)
  6. 3.6 Global Interleukin 1 (IL1) Company Manufacturing Base and Headquarters
  7. 3.7 Global Interleukin 1 (IL1) Company Product Type and Application
  8. 3.8 Global Interleukin 1 (IL1) Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Interleukin 1 (IL1) Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Interleukin 1 (IL1) Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Interleukin 1 (IL1) Market by Type
  1. 4.1 Interleukin 1 (IL1) Type Introduction
  2. 4.1.1 APX-002
  3. 4.1.2 Diacerein CR
  4. 4.1.3 Canakinumab
  5. 4.1.4 IR-1000
  6. 4.1.5 Others
  7. 4.2 Global Interleukin 1 (IL1) Sales Volume by Type
  8. 4.2.1 Global Interleukin 1 (IL1) Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Interleukin 1 (IL1) Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Interleukin 1 (IL1) Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Interleukin 1 (IL1) Sales Value by Type
  12. 4.3.1 Global Interleukin 1 (IL1) Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Interleukin 1 (IL1) Sales Value by Type (2021-2032)
  14. 4.3.3 Global Interleukin 1 (IL1) Sales Value Share by Type (2021-2032)
5 Interleukin 1 (IL1) Market by Application
  1. 5.1 Interleukin 1 (IL1) Application Introduction
  2. 5.1.1 Fallopian Tube Cancer
  3. 5.1.2 Esophageal Cancer
  4. 5.1.3 Bechcer Disease
  5. 5.1.4 Bladder Cancer
  6. 5.1.5 Others
  7. 5.2 Global Interleukin 1 (IL1) Sales Volume by Application
  8. 5.2.1 Global Interleukin 1 (IL1) Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Interleukin 1 (IL1) Sales Volume by Application (2021-2032)
  10. 5.2.3 Global Interleukin 1 (IL1) Sales Volume Share by Application (2021-2032)
  11. 5.3 Global Interleukin 1 (IL1) Sales Value by Application
  12. 5.3.1 Global Interleukin 1 (IL1) Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global Interleukin 1 (IL1) Sales Value by Application (2021-2032)
  14. 5.3.3 Global Interleukin 1 (IL1) Sales Value Share by Application (2021-2032)
6 Interleukin 1 (IL1) Regional Sales and Value Analysis
  1. 6.1 Global Interleukin 1 (IL1) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Interleukin 1 (IL1) Sales by Region (2021-2032)
  3. 6.2.1 Global Interleukin 1 (IL1) Sales by Region: 2021-2026
  4. 6.2.2 Global Interleukin 1 (IL1) Sales by Region (2027-2032)
  5. 6.3 Global Interleukin 1 (IL1) Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Interleukin 1 (IL1) Sales Value by Region (2021-2032)
  7. 6.4.1 Global Interleukin 1 (IL1) Sales Value by Region: 2021-2026
  8. 6.4.2 Global Interleukin 1 (IL1) Sales Value by Region (2027-2032)
  9. 6.5 Global Interleukin 1 (IL1) Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Interleukin 1 (IL1) Sales Value (2021-2032)
  12. 6.6.2 North America Interleukin 1 (IL1) Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Interleukin 1 (IL1) Sales Value (2021-2032)
  15. 6.7.2 Europe Interleukin 1 (IL1) Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Interleukin 1 (IL1) Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Interleukin 1 (IL1) Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Interleukin 1 (IL1) Sales Value (2021-2032)
  21. 6.9.2 South America Interleukin 1 (IL1) Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Interleukin 1 (IL1) Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Interleukin 1 (IL1) Sales Value Share by Country, 2025 VS 2032
7 Interleukin 1 (IL1) Country-level Sales and Value Analysis
  1. 7.1 Global Interleukin 1 (IL1) Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Interleukin 1 (IL1) Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Interleukin 1 (IL1) Sales by Country (2021-2032)
  4. 7.3.1 Global Interleukin 1 (IL1) Sales by Country (2021-2026)
  5. 7.3.2 Global Interleukin 1 (IL1) Sales by Country (2027-2032)
  6. 7.4 Global Interleukin 1 (IL1) Sales Value by Country (2021-2032)
  7. 7.4.1 Global Interleukin 1 (IL1) Sales Value by Country (2021-2026)
  8. 7.4.2 Global Interleukin 1 (IL1) Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Interleukin 1 (IL1) Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Interleukin 1 (IL1) Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Interleukin 1 (IL1) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis AG
  2. 8.1.1 Novartis AG Company Information
  3. 8.1.2 Novartis AG Business Overview
  4. 8.1.3 Novartis AG Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novartis AG Interleukin 1 (IL1) Product Portfolio
  6. 8.1.5 Novartis AG Recent Developments
  7. 8.2 AbbVie Inc
  8. 8.2.1 AbbVie Inc Company Information
  9. 8.2.2 AbbVie Inc Business Overview
  10. 8.2.3 AbbVie Inc Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 AbbVie Inc Interleukin 1 (IL1) Product Portfolio
  12. 8.2.5 AbbVie Inc Recent Developments
  13. 8.3 XBiotech Inc
  14. 8.3.1 XBiotech Inc Company Information
  15. 8.3.2 XBiotech Inc Business Overview
  16. 8.3.3 XBiotech Inc Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 XBiotech Inc Interleukin 1 (IL1) Product Portfolio
  18. 8.3.5 XBiotech Inc Recent Developments
  19. 8.4 TWi Biotechnology Inc
  20. 8.4.1 TWi Biotechnology Inc Company Information
  21. 8.4.2 TWi Biotechnology Inc Business Overview
  22. 8.4.3 TWi Biotechnology Inc Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 TWi Biotechnology Inc Interleukin 1 (IL1) Product Portfolio
  24. 8.4.5 TWi Biotechnology Inc Recent Developments
  25. 8.5 Swedish Orphan Biovitrum AB
  26. 8.5.1 Swedish Orphan Biovitrum AB Company Information
  27. 8.5.2 Swedish Orphan Biovitrum AB Business Overview
  28. 8.5.3 Swedish Orphan Biovitrum AB Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Swedish Orphan Biovitrum AB Interleukin 1 (IL1) Product Portfolio
  30. 8.5.5 Swedish Orphan Biovitrum AB Recent Developments
  31. 8.6 Regeneron Pharmaceuticals Inc
  32. 8.6.1 Regeneron Pharmaceuticals Inc Company Information
  33. 8.6.2 Regeneron Pharmaceuticals Inc Business Overview
  34. 8.6.3 Regeneron Pharmaceuticals Inc Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Regeneron Pharmaceuticals Inc Interleukin 1 (IL1) Product Portfolio
  36. 8.6.5 Regeneron Pharmaceuticals Inc Recent Developments
  37. 8.7 R Pharm
  38. 8.7.1 R Pharm Company Information
  39. 8.7.2 R Pharm Business Overview
  40. 8.7.3 R Pharm Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 R Pharm Interleukin 1 (IL1) Product Portfolio
  42. 8.7.5 R Pharm Recent Developments
  43. 8.8 Peptinov SAS
  44. 8.8.1 Peptinov SAS Company Information
  45. 8.8.2 Peptinov SAS Business Overview
  46. 8.8.3 Peptinov SAS Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Peptinov SAS Interleukin 1 (IL1) Product Portfolio
  48. 8.8.5 Peptinov SAS Recent Developments
  49. 8.9 Orphit SAS
  50. 8.9.1 Orphit SAS Company Information
  51. 8.9.2 Orphit SAS Business Overview
  52. 8.9.3 Orphit SAS Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Orphit SAS Interleukin 1 (IL1) Product Portfolio
  54. 8.9.5 Orphit SAS Recent Developments
  55. 8.10 Optimum Therapeutics LLC
  56. 8.10.1 Optimum Therapeutics LLC Company Information
  57. 8.10.2 Optimum Therapeutics LLC Business Overview
  58. 8.10.3 Optimum Therapeutics LLC Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Optimum Therapeutics LLC Interleukin 1 (IL1) Product Portfolio
  60. 8.10.5 Optimum Therapeutics LLC Recent Developments
  61. 8.11 Opsona Therapeutics Ltd
  62. 8.11.1 Opsona Therapeutics Ltd Company Information
  63. 8.11.2 Opsona Therapeutics Ltd Business Overview
  64. 8.11.3 Opsona Therapeutics Ltd Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Opsona Therapeutics Ltd Interleukin 1 (IL1) Product Portfolio
  66. 8.11.5 Opsona Therapeutics Ltd Recent Developments
  67. 8.12 Omnitura Therapeutics Inc
  68. 8.12.1 Omnitura Therapeutics Inc Company Information
  69. 8.12.2 Omnitura Therapeutics Inc Business Overview
  70. 8.12.3 Omnitura Therapeutics Inc Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Omnitura Therapeutics Inc Interleukin 1 (IL1) Product Portfolio
  72. 8.12.5 Omnitura Therapeutics Inc Recent Developments
  73. 8.13 Immune Response BioPharma Inc
  74. 8.13.1 Immune Response BioPharma Inc Company Information
  75. 8.13.2 Immune Response BioPharma Inc Business Overview
  76. 8.13.3 Immune Response BioPharma Inc Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Immune Response BioPharma Inc Interleukin 1 (IL1) Product Portfolio
  78. 8.13.5 Immune Response BioPharma Inc Recent Developments
  79. 8.14 Exicure Inc
  80. 8.14.1 Exicure Inc Company Information
  81. 8.14.2 Exicure Inc Business Overview
  82. 8.14.3 Exicure Inc Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Exicure Inc Interleukin 1 (IL1) Product Portfolio
  84. 8.14.5 Exicure Inc Recent Developments
  85. 8.15 Cell Medica Ltd
  86. 8.15.1 Cell Medica Ltd Company Information
  87. 8.15.2 Cell Medica Ltd Business Overview
  88. 8.15.3 Cell Medica Ltd Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Cell Medica Ltd Interleukin 1 (IL1) Product Portfolio
  90. 8.15.5 Cell Medica Ltd Recent Developments
  91. 8.16 Apexigen Inc
  92. 8.16.1 Apexigen Inc Company Information
  93. 8.16.2 Apexigen Inc Business Overview
  94. 8.16.3 Apexigen Inc Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Apexigen Inc Interleukin 1 (IL1) Product Portfolio
  96. 8.16.5 Apexigen Inc Recent Developments
  97. 8.17 Anacor Pharmaceuticals Inc
  98. 8.17.1 Anacor Pharmaceuticals Inc Company Information
  99. 8.17.2 Anacor Pharmaceuticals Inc Business Overview
  100. 8.17.3 Anacor Pharmaceuticals Inc Interleukin 1 (IL1) Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Anacor Pharmaceuticals Inc Interleukin 1 (IL1) Product Portfolio
  102. 8.17.5 Anacor Pharmaceuticals Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Interleukin 1 (IL1) Value Chain Analysis
  2. 9.1.1 Interleukin 1 (IL1) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Interleukin 1 (IL1) Sales Mode & Process
  6. 9.2 Interleukin 1 (IL1) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Interleukin 1 (IL1) Distributors
  9. 9.2.3 Interleukin 1 (IL1) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst